And while we are on the subject of molecules in urine, the FDA is now considering using biomarker assisted safety assessment for new pharmaceuticals. This is bureaucracy speak for looking for particular molecules that indicate trouble in saliva, blood, and urine. It is an interesting way to go, as it will standardize certain patient feedbacks in late stage drug testing. It will also drive down the cost of testing, unless this is added on as further documentation on top of what already exist. (I would not put that beyond the FDA.)